Literature DB >> 2159442

The use of a genotypic marker to demonstrate clonal dominance during the growth and metastasis of a human breast carcinoma in nude mice.

J E Price1, C Bell, P Frost.   

Abstract

When a mixture of 11 clones of a human breast carcinoma (MDA-MB-435)--each clone transfected with pSV2neo and identified as having a unique insertion site of the gene--was injected into nude mice, the resulting tumors were found to contain only one clone (Neo 24). This clone, identified by the unique restriction fragments on Southern blot analyses, was also found in metastases recovered from the lungs and lymph nodes of the animals. The individual clones showed no differences in in vitro growth, while in vivo the Neo 24 cells produced the largest tumors. Thus, one explanation for the observed clonal dominance in this study could be the more rapid growth in vivo of the Neo 24 cells. This study illustrates how an introduced selectable gene marker can be used in lineage studies of human tumor cell populations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159442     DOI: 10.1002/ijc.2910450532

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Tumor Heterogeneity--A 'Contemporary Concept' Founded on Historical Insights and Predictions.

Authors:  Danny R Welch
Journal:  Cancer Res       Date:  2016-01-03       Impact factor: 12.701

2.  Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.

Authors:  Y Li; Z Y Tang; S L Ye; Y K Liu; J Chen; Q Xue; J Chen; D M Gao; W H Bao
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Human lung adenocarcinoma cell lines with different lung colonization potential (LCP), and a correlation between expression of sialosyl dimeric Le(x) (defined by MAb FH6) and LCP.

Authors:  H Inufusa; N Kojima; M Yasutomi; S Hakomori
Journal:  Clin Exp Metastasis       Date:  1991 May-Jun       Impact factor: 5.150

4.  Growth advantage ("clonal dominance") of metastatically competent tumor cell variants expressed under selective two- or three-dimensional tissue culture conditions.

Authors:  J W Rak; R S Kerbel
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-09       Impact factor: 2.416

5.  Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D.

Authors:  Ji-Cheng Zhang; Zuo-Ren Wang; Yan-Juan Cheng; Ding-Zhong Yang; Jing-Sen Shi; Ai-Lin Liang; Ning-Na Liu; Xiao-Min Wang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 6.  Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions.

Authors:  J Guy Lyons; Erwin Lobo; Anna M Martorana; Mary R Myerscough
Journal:  Clin Exp Metastasis       Date:  2007-12-11       Impact factor: 5.150

7.  The nude mouse as an in vivo model for human breast cancer invasion and metastasis.

Authors:  N Brünner; B Boysen; J Rømer; M Spang-Thomsen
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Comparative lesion sequencing provides insights into tumor evolution.

Authors:  Siân Jones; Wei-Dong Chen; Giovanni Parmigiani; Frank Diehl; Niko Beerenwinkel; Tibor Antal; Arne Traulsen; Martin A Nowak; Christopher Siegel; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Joseph Willis; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 11.205

9.  Clonal dominance detected in metastases but not primary tumors of retrovirally marked human breast carcinoma injected into nude mice.

Authors:  K Cornetta; A Moore; M Johannessohn; G W Sledge
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

10.  Growth and metastasis of human breast cancers in athymic nude mice.

Authors:  M S Murthy; E F Scanlon; M L Jelachich; S Klipstein; R A Goldschmidt
Journal:  Clin Exp Metastasis       Date:  1995-01       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.